Drug Combination Details
| General Information of the Combination (ID: C31241) | |||||
|---|---|---|---|---|---|
| Name | Thymoquinone NP Info | + | Imatinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Colorectal cancer
[ICD-11: 2B91]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ABCB1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | ABCG2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SLC22A1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
TQ potentiates IM efficacy on HCT116 cells via uptake/efflux genes modulation. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Thymoquinone chemosensitizes human colorectal cancer cells to imatinib via uptake/efflux genes modulation. Clin Exp Pharmacol Physiol. 2021 Jun;48(6):911-920. | |||
